Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2015

01-04-2015 | Case report

Bevacizumab/everolimus/sorafenib/sunitinib

Gallbladder complications: 6 case reports

Published in: Reactions Weekly | Issue 1/2015

Login to get access

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
…
Footnotes
1
identified through a search of a radiology database at a tertiary cancer center from January 2005 to September 2012
 
Literature
Tirumani SH, et al. Gallbladder complications associated with molecular targeted therapies: Clinical and imaging features. Clinical Imaging 38: 50-55, No. 1, 1 Jan 2014 - USACrossRefPubMed
Metadata
Title
Bevacizumab/everolimus/sorafenib/sunitinib
Gallbladder complications: 6 case reports
Publication date
01-04-2015
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2015
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-015-9149-4

Other articles of this Issue 1/2015

Reactions Weekly 1/2015 Go to the issue

Case report

Docetaxel/paclitaxel

Case report

Cetuximab/mineral oil

Case report

Prednisolone

Case report

Sunitinib

Clinical study

Methotrexate: no increased risk of lung disorders

Case report

Phenprocoumon